Skip to content

Comparison of auricular and renal complications of a single and divided dose intravenous aminoglycoside

Comparative study of auricular and renal complications of divided and single dose Gentamicin in patients with sepsis syndrome.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201104125584N2
Enrollment
80
Registered
2012-04-19
Start date
2010-10-02
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis Syndrome. Sepsis, unspecified

Interventions

Intervention 1: Single dose group: Patients in this group will receive intravenous gentamicin 1.7 mg/kg in a single dose daily for an unspecified period of time which is depended on their septic condi
Treatment - Drugs
Single dose group: Patients in this group will receive intravenous gentamicin 1.7 mg/kg in a single dose daily for an unspecified period of time which is depended on their septic condition.
Divided dose group: Patients in this group will receive intravenous gentamicin 1.7 mg/kg/dose in two or three doses per day for an unspecified period of time which is depended on their septic conditio

Sponsors

Vice Chancellor for Research of Tabriz University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (to be 12 to 55 years old; to have a normal renal function; to have septic syndrome without any underlying conditions) Exclusion criteria: (to have a positive blood culture with resistance to gentamicin)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Blood urea nitrogen level. Timepoint: at the treatment initiation and seven days after the initiation of the treatment. Method of measurement: Biochemistry laboratorial blood test.;Blood creatinine level. Timepoint: at the treatment initiation and seven days after the initiation of the treatment. Method of measurement: Biochemistry laboratorial blood test.;Audiometry. Timepoint: at the treatment initiation and seven days after the initiation of the treatment. Method of measurement: Using an audiometry device.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Parviz Saleh

Tabriz University of Medical Sciences

p.zzss@yahoo.com+98 41 1334 4668

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026